No part of this publication may be reproduced, amended, or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without explicit permission in writing from KDIGO. Details on how to seek reprints, permission for reproduction or translation, and further information about KDIGO s permissions policies can be obtained by contacting Melissa Thompson, Chief Operating Of cer, at melissa.thompson@kdigo.org. To the fullest extent of the law, neither KDIGO, Kidney International, nor the authors, contributors, or editors assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. notice www.kidney-international.org Foreword With the growing awareness that chronic kidney disease (CKD) is a major global health problem, Kidney Disease: Improving Global Outcomes (KDIGO) was established in 2003 with its stated mission to improve the care and out- comes of patients with kidney disease worldwide through promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines. Since 2003, KDIGO has developed a catalog of clinical practice guidelines informing the care of patients with, or at risk of, developing kidney diseases. Currently, KDIGO is updating 2 existing guidelines on the Management of Blood Pressure in CKD and Glomerular Diseases, respectively. In addition, KDIGO has recently published its rst guideline related to Diabetes Management in CKD. High blood pressure (BP) is closely related to adverse kidney and cardiovascular outcomes in CKD. Thus, KDIGO published its rst guideline for the management of BP in CKD in 2012. The guideline was derived from a signi cant effort by the Work Group to summarize the evidence on this topic available through 2011. 